Bayer Pharmaceuticals Corp. has suspended sales of Trasylol, a drug used to control bleeding during heart surgery, after pressure by the FDA. The suspension of sales of Trasylol is due to a Canadian study which may have found an increased risk of death associated with the drug’s use. The FDA and Bayer are examining the study which was stopped before its expected conclusion.
Trasylol appeares to increase the risk for death compared to two other antifibrinolytic drugs used in the study. Antifibrinolytic drugs are used to slow the breakdown of blood clots and subsequent excessive bleeding. The Canadian study was stopped prematurely when researchers noticed the increased risk of death. The preliminary data from this terminated study also suggested that fewer patients receiving the drug experienced serious bleeding events.
For more information on this subject, please refer to the section on Drugs, Medical Devices, and Implants.